Scrip
New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancer patients
20 July 2009
Malini Guha
The US labelling of
Lilly (ImClone)/
Bristol-Myers Squibb 's Erbitux (cetuximab) and
Amgen's Vectibix (panitumumab) have been revised to highlight the fact that the EGFR-targeted drugs are not recommended for use in the approximately 40% of metastatic colorectal cancer (mCRC) patients who have a...
Please Login to read the full article.
20 July 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- Mixed Phase III results for Erbitux in first-line colorectal cancer
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
